Novartis nAMD Treatment Brolucizumab Shows Superiority Against Regeneron’s Eylea at Two YearsAllbiopro2018-10-30T08:59:11+09:0010월 30th, 2018|
Pfizer and Novartis Ink Deal to Test Combination Therapies for NASHAllbiopro2018-10-30T08:58:20+09:0010월 30th, 2018|
Eli Lilly Makes a Big Bet on RNAi Therapies With Dicerna DealAllbiopro2018-10-30T08:57:54+09:0010월 30th, 2018|
Careful, reps: Doctors are watching, FDA promo police’s latest rebuke showsAllbiopro2018-10-30T08:57:28+09:0010월 30th, 2018|
Takeda tags another Shire drug for sale to win key nod for $62B dealAllbiopro2018-10-30T08:57:02+09:0010월 30th, 2018|
Johnson & Johnson down to its final Zytiga defenses as judge puts temporary kibosh on genericsAllbiopro2018-10-30T08:56:36+09:0010월 30th, 2018|
Aspen Pharmacare to build $235M production facility in South Africa, add hundreds of jobsAllbiopro2018-10-30T08:56:09+09:0010월 30th, 2018|
Roche, Novartis are revving up next-generation eye drugs, but are they true contenders?Allbiopro2018-10-30T08:55:42+09:0010월 30th, 2018|
Johnson & Johnson to open JLabs virtual networking pod in PhiladelphiaAllbiopro2018-10-30T08:55:16+09:0010월 30th, 2018|
Days after Alexion deal, Dicerna pens $100M upfront RNAi research pact with Eli LillyAllbiopro2018-10-30T08:54:51+09:0010월 30th, 2018|
Safety update sets up filings for Esperion cholesterol drugAllbiopro2018-10-30T08:54:24+09:0010월 30th, 2018|
Turning of the tide: High potential for oligos, says surveyAllbiopro2018-10-30T08:53:58+09:0010월 30th, 2018|
Avid to triple process dev capacity on early-stage demandAllbiopro2018-10-30T08:53:08+09:0010월 30th, 2018|
Repeated interferon stimulation creates innate immune memoryAllbiopro2018-10-30T08:51:46+09:0010월 30th, 2018|
